Key result
Empagliflozin reduces kidney disease progression or CV death vs placebo in CKD.
Why the study?
Does empagliflozin reduce the risk of progression of kidney disease or death from cardiovascular causes in patients with chronic kidney disease?
Does empagliflozin reduce the risk of progression of kidney disease or death from cardiovascular causes in patients with chronic kidney disease?
Empagliflozin reduces the risk of kidney disease progression or cardiovascular death in patients with chronic kidney disease.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“The cardiovascular-kidney-metabolic guidelines endorse SGLT2 inhibitors for patients without diabetes mellitus who have albuminuria (urinary albumin-to-creatinine ratio 30-199 mg/g), expanding cardiorenal protection to earlier disease stages.”
Supports empagliflozin use in CKD to reduce progression and CV death; extends SGLT2-inhibitor benefits across diabetes status.
Among a wide range of patients with chronic kidney disease who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease or death from cardiovascular causes than placebo. (Funded by Boehringer Ingelheim and others; EMPA-KIDNEY ClinicalTrials.gov number, NCT03594110; EudraCT number, 2017-002971-24.).
No takes yet. Share an insight, caveat, or question.
William G. Herrington (2022) studied this question. Empagliflozin lowered the risk of kidney disease progression or cardiovascular death compared to placebo in patients with chronic kidney disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: